Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Streptococcus Salivarius K12 for Oral Mucositis in Head and Neck Cancer Radiotherapy
NCT05918224Phase 2Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2022
- Primary completion
- Nov 2022
- Modality
- Yeast Strains, Defined Consortia, Bacterial Strains
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in oral mucositis (OM) comparing S. salivarius K12 with Placebo (2 arms). Primary endpoint: Incidence of Severe Oral Mucositis (WHO grade ≥3). Started Jan 2022; status: completed.
02
Drugs
Streptococcus salivarius K12
03
Conditions
oral mucositis (OM)
Beyond the preview
Go deeper on NCT05918224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05918224.